Adding Nintedanib to Frontline Treatment Active in Advanced Ovarian Cancer

Share this content:
Nintedanib is an active first-line treatment that significantly improves progression-free survival for women with advanced ovarian cancer.
Nintedanib is an active first-line treatment that significantly improves progression-free survival for women with advanced ovarian cancer.

Nintedanib in combination with carboplatin and paclitaxel is an active first-line treatment that significantly improves progression-free survival for women with advanced ovarian cancer, according to a new study published online ahead of print in the journal The Lancet Oncology. However, the regimen is associated with more gastrointestinal adverse events.1

For the double-blind, phase 3 trial, researchers enrolled 1366 chemotherapy-naïve patients with stage 2B to 4 ovarian cancer who underwent upfront debulking surgery.

Patients were randomly assigned 2:1 to receive 6 cycles of carboplatin AUC 5 or 6 mg/mL per minute plus paclitaxel 175 mg/m2 with nintedanib 200 mg or placebo twice daily on days 2 to 21 of every 3-week cycle for up to 120 weeks.

Results showed that median progression-free survival was 17.2 months (95% CI, 16.6 - 19.9) in the nintedanib group compared with 16.6 months (95% CI, 13.9 - 19.1) in the placebo group (HR, 0.84; 95% CI, 0.72 - 0.98; P = .024). A total of 53% of patients in the nintedanib group experienced disease progression or death vs 58% of those in the placebo group.

RELATED: Adjuvant Hormonal Therapy Is Safe in Epithelial Ovarian Cancer

In regard to safety, grade 3 to 4 diarrhea was experienced by nearly 22% of patients in the nintedanib arm compared with 2% of those in the placebo arm.

Other common adverse events were neutropenia, thrombocytopenia, and anemia. Of note, 3 patients in the nintedanib and 1 in the placebo group died to due to drug-related adverse events.

“Future studies should focus on improving patient selection and optimization tolerability,” the authors concluded.

Reference

  1. du Bois A, Kristensen G, Ray-Coquard I, et al. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial [published online ahead of print on November 15, 2015]. Lancet Oncol. doi: 10.1016/S1470-2045(15)00366-6.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters